Moreover, the nonsteroidal FXR agonist cilofexor is site-specific and contributes to reducing liver lipid content in patients with MASH without altering blood levels of lipids or disturbing insulin resistance [93]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.